Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01332279
Other study ID # OER-HN-038
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date April 2011
Est. completion date May 2011

Study information

Verified date March 2023
Source Fox Chase Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of giving everolimus (RAD001) and erlotinib hydrochloride together with radiation therapy in treating patients with recurrent head and neck cancer previously treated with radiation therapy. RAD001 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving RAD001 and erlotinib hydrochloride together with radiation therapy may kill more tumor cells.


Description:

PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) and safety of RAD001 given concurrently with external beam radiation therapy (EBRT) in the re-irradiation setting for head and neck cancer. SECONDARY OBJECTIVES: I. Obtain preliminary data on response rate. II. Determine progression-free survival at 6 and 12 months and overall survival. III. Perform correlative studies to evaluate and characterize biological features of recurrent or second primary tumors, as well as to follow surrogates of mammalian target of rapamycin (mTOR), epidermal growth factor receptor (EGFR) and hypoxia-inducible factor 1-alpha (HIF-1α) inhibition. OUTLINE: This is a dose-escalation study of everolimus and erlotinib hydrochloride. Patients receive RAD001 orally (PO) and erlotinib hydrochloride PO once daily (QD). Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT twice daily (BID) 5 days a week for 5 weeks. After completion of study treatment, patients are followed up for 2 years.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Recurrent aerodigestive cancers of squamous cell histology of the head and neck, or those who have a second head and neck primary cancer, who have received prior radiation therapy for a head and neck malignancy with curative intent - Patients must locally advanced disease, without distant metastases; measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) is not required - Patients who had surgery for recurrent disease or a second primary in a previously radiated field are eligible if their surgical pathology specimen from the resection exhibits high risk features such as positive margins or extracapsular extension - Patient may have more than one recurrence as long as the current recurrence occurs at least >= 6 months after the end of prior radiation therapy - Only one prior course of radiotherapy to the head and neck region is allowed; prior chemotherapy is allowed - Based on prior radiation treatment records, most (> 50%) of the tumor volume must have been in areas previously irradiated to >= 45 Gy without exceeding spinal cord tolerance (combining previous and future radiation dose to the spinal cord of =< 50 Gy) - The previous total radiation dose must not have exceeded a maximum dose of 75 Gy - Karnofsky Performance Status > 70 or Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 - Patients must sign study-specific informed consent and Health Insurance Portability and Accountability Act (HIPAA) forms - Patient must be willing to have percutaneous endoscopic gastrostomy (PEG) placement if necessary - Patients must be able to swallow oral medications - Patients and/or their partners of childbearing potential are required to use adequate birth control during and for 6 months after completion of study therapy - Leukocytes >= 3,000/ul - Absolute neutrophil count >= 1,500/ul - Platelets >= 100,000/ul - Total bilirubin =< institutional upper limit of normal - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper institutional limits - OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - Hemoglobin >= 9 g/dL - Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L; AND fasting triglycerides =< 2.5 x upper limit of normal (ULN); NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication at any point prior to the initiation of therapy - International normalized ratio (INR) =< 1.5; (anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at time of randomization) Exclusion Criteria: - Patient has history of using erlotinib or any other EGFR inhibitors (prior C225/Cetuximab treatment is allowed if given with radiation therapy, but treatment must have been completed at least 6 months prior to study entry) - Patient has history of receiving RAD001 or any other mTOR inhibitors - Patient is known to be allergic to any type of EGFR tyrosine kinase inhibitors or mTOR inhibitors - Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed - As judged by the investigator, any evidence of severe or uncontrolled psychiatric or systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease); history of noncompliance to medical regimens - Pregnant or breast-feeding women or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001) - Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort; these medications can be discontinued one week prior to enrollment if medically feasible - Treatment on any other clinical protocols or with a non-approved or investigational drug within 4 weeks before Day 1 of study treatment - Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) - Known active connective tissue disorders, such as lupus or scleroderma which, in the opinion of the treating physician, may put the patient at high risk for radiation toxicity - Patients with known human immunodeficiency virus (HIV) infection and/or acquired immune deficiency (AIDS) - Patients with known multiple sclerosis - Patients with nasopharyngeal carcinoma are excluded; other malignancies within the past 3 years which actively require ongoing treatment except for treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin - Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with RAD001; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines - Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: - Symptomatic congestive heart failure of New York heart Association Class III or IV - Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction =< 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease - Severely impaired lung function as defined as spirometry and diffusion capacity of carbon monoxide (DLCO) that is 50% of the normal predicted value and/or oxygen (O2) saturation that is 88% or less at rest on room air - Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN - Active (acute or chronic) or uncontrolled severe infections - Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis; Note: A detailed assessment of hepatitis B/C medical history and risk factors must be done at screening for all patients; hepatitis B virus (HBV) deoxyribonucleic acid (DNA) and hepatitis C virus (HCV) ribonucleic acid (RNA) polymerase chain reaction (PCR) testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection - Steroid or supplemental oxygen required for exacerbations of chronic obstructive lung disease - Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) - Current active smokers are excluded; these patients may be enrolled if they report that they have refrained from smoking for a minimum of 7 days - Patients with an active, bleeding diathesis - Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
everolimus
Given PO
erlotinib hydrochloride
Given PO
Procedure:
biopsy
Correlative studies
Other:
laboratory biomarker analysis
Correlative studies
immunohistochemistry staining method
Correlative studies
Genetic:
polyacrylamide gel electrophoresis
Correlative studies
Other:
pharmacological study
Correlative studies
Radiation:
external beam radiation therapy
Undergo EBRT
Genetic:
microarray analysis
Correlative studies

Locations

Country Name City State
United States Fox Chase Cancer Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Fox Chase Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary MTD of RAD001, erlotinib and radiotherapy in the re-irradiation setting Establish the safety profile of this regimen and establish the MTD of RAD001 with/without erlotinib in conjunction with RT. During the period of radiation treatment or within the first 2 weeks after the completion of radiotherapy
Secondary Preliminary data on response rate Overall response rate will be estimated with its 95% confidence interval by dose level and will be compared with historical data and our own extensive experience at Fox Chase. Response will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. At 5 and 13 weeks post-radiation therapy and then every 3 months until disease progression or until patient comes off study
Secondary Overall survival Overall survival will be estimated using Kaplan-Meier curves and will be compared with historical data and our own extensive experience at Fox Chase. every 6 months
Secondary Biological features of recurrent or second primary tumors, as well as surrogates of mTOR, EGFR and HIF-1a inhibition Correlative assessment of biomarkers as well as surrogates of response will be performed. Biological endpoints (protein expression of EGFR, pEGFR, EGFR amplification, Akt/pAkt, PS6Kinase, HIF-1 a and its associated hypoxia induced angiogenesis-associated genes) will use linear or nonlinear mixed models, as appropriate. Associations between study drug dose and biological endpoints will be similarly analyzed. At baseline and week 4
See also
  Status Clinical Trial Phase
Completed NCT01469429 - Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Phase 1/Phase 2
Withdrawn NCT04041141 - Oral Stent Device for Radiation Treatments of Oral Cancers
Completed NCT00049283 - Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Phase 1
Completed NCT00407810 - Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00096512 - S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT01637194 - Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Phase 1
Completed NCT00033618 - Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Phase 2
Completed NCT01816841 - Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT04059861 - Ultrasound in Tongue Cancer- a Help to Decide Depth of Invasion and to Improve the Surgical Margin N/A
Recruiting NCT01854021 - Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer N/A
Completed NCT01816984 - PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT01674374 - Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Phase 2
Terminated NCT01528137 - Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Phase 1
Completed NCT04337853 - Radiotherapy of Tongue Cancer Using an Intraoral Stent Phase 1
Completed NCT01806675 - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Phase 1/Phase 2
Active, not recruiting NCT01847326 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Phase 1
Terminated NCT02177838 - Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer N/A
Completed NCT00114283 - Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase 2
Completed NCT04126226 - Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy N/A